Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1993 May;67(5):869–876. doi: 10.1038/bjc.1993.164

Antisense technology for cancer therapy: does it make sense?

G Carter 1, N R Lemoine 1
PMCID: PMC1968450  PMID: 8494718

Full text

PDF
869

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Agrawal S., Temsamani J., Tang J. Y. Pharmacokinetics, biodistribution, and stability of oligodeoxynucleotide phosphorothioates in mice. Proc Natl Acad Sci U S A. 1991 Sep 1;88(17):7595–7599. doi: 10.1073/pnas.88.17.7595. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Arch R., Wirth K., Hofmann M., Ponta H., Matzku S., Herrlich P., Zöller M. Participation in normal immune responses of a metastasis-inducing splice variant of CD44. Science. 1992 Jul 31;257(5070):682–685. doi: 10.1126/science.1496383. [DOI] [PubMed] [Google Scholar]
  3. Beaudry A. A., Joyce G. F. Directed evolution of an RNA enzyme. Science. 1992 Jul 31;257(5070):635–641. doi: 10.1126/science.1496376. [DOI] [PubMed] [Google Scholar]
  4. Birchenall-Roberts M. C., Ferrer C., Ferris D., Falk L. A., Kasper J., White G., Ruscetti F. W. Inhibition of murine monocyte proliferation by a colony-stimulating factor-1 antisense oligodeoxynucleotide. Evidence for autocrine regulation. J Immunol. 1990 Nov 15;145(10):3290–3296. [PubMed] [Google Scholar]
  5. Boutorine A. S., Boiziau C., Le Doan T., Toulmé J. J., Hélène C. Effect of the terminal phosphate derivatization of beta- and alpha-oligodeoxynucleotides on their antisense activity in protein biosynthesis, stability and uptake by eucaryotic cells. Biochimie. 1992 May;74(5):485–489. doi: 10.1016/0300-9084(92)90089-w. [DOI] [PubMed] [Google Scholar]
  6. Brown D., Yu Z. P., Miller P., Blake K., Wei C., Kung H. F., Black R. J., Ts'o P. O., Chang E. H. Modulation of ras expression by anti-sense, nonionic deoxyoligonucleotide analogs. Oncogene Res. 1989;4(4):243–252. [PubMed] [Google Scholar]
  7. Cameron F. H., Jennings P. A. Specific gene suppression by engineered ribozymes in monkey cells. Proc Natl Acad Sci U S A. 1989 Dec;86(23):9139–9143. doi: 10.1073/pnas.86.23.9139. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Chang E. H., Miller P. S., Cushman C., Devadas K., Pirollo K. F., Ts'o P. O., Yu Z. P. Antisense inhibition of ras p21 expression that is sensitive to a point mutation. Biochemistry. 1991 Aug 27;30(34):8283–8286. doi: 10.1021/bi00098a001. [DOI] [PubMed] [Google Scholar]
  9. Citro G., Perrotti D., Cucco C., D'Agnano I., Sacchi A., Zupi G., Calabretta B. Inhibition of leukemia cell proliferation by receptor-mediated uptake of c-myb antisense oligodeoxynucleotides. Proc Natl Acad Sci U S A. 1992 Aug 1;89(15):7031–7035. doi: 10.1073/pnas.89.15.7031. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Cohen J. S. Antisense oligodeoxynucleotides as antiviral agents. Antiviral Res. 1991 Sep;16(2):121–133. doi: 10.1016/0166-3542(91)90019-n. [DOI] [PubMed] [Google Scholar]
  11. Connor J., Huang L. pH-sensitive immunoliposomes as an efficient and target-specific carrier for antitumor drugs. Cancer Res. 1986 Jul;46(7):3431–3435. [PubMed] [Google Scholar]
  12. Cooney M., Czernuszewicz G., Postel E. H., Flint S. J., Hogan M. E. Site-specific oligonucleotide binding represses transcription of the human c-myc gene in vitro. Science. 1988 Jul 22;241(4864):456–459. doi: 10.1126/science.3293213. [DOI] [PubMed] [Google Scholar]
  13. Cope F. O., Wille J. J. Retinoid receptor antisense DNAs inhibit alkaline phosphatase induction and clonogenicity in malignant keratinocytes. Proc Natl Acad Sci U S A. 1989 Jul;86(14):5590–5594. doi: 10.1073/pnas.86.14.5590. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Cotten M., Birnstiel M. L. Ribozyme mediated destruction of RNA in vivo. EMBO J. 1989 Dec 1;8(12):3861–3866. doi: 10.1002/j.1460-2075.1989.tb08564.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Daaka Y., Wickstrom E. Target dependence of antisense oligodeoxynucleotide inhibition of c-Ha-ras p21 expression and focus formation in T24-transformed NIH3T3 cells. Oncogene Res. 1990;5(4):267–275. [PubMed] [Google Scholar]
  16. Dolnick B. J. Antisense agents in cancer research and therapeutics. Cancer Invest. 1991;9(2):185–194. doi: 10.3109/07357909109044229. [DOI] [PubMed] [Google Scholar]
  17. Gao W. Y., Han F. S., Storm C., Egan W., Cheng Y. C. Phosphorothioate oligonucleotides are inhibitors of human DNA polymerases and RNase H: implications for antisense technology. Mol Pharmacol. 1992 Feb;41(2):223–229. [PubMed] [Google Scholar]
  18. Gewirtz A. M., Calabretta B. A c-myb antisense oligodeoxynucleotide inhibits normal human hematopoiesis in vitro. Science. 1988 Dec 2;242(4883):1303–1306. doi: 10.1126/science.2461588. [DOI] [PubMed] [Google Scholar]
  19. Giles R. V., Tidd D. M. Increased specificity for antisense oligodeoxynucleotide targeting of RNA cleavage by RNase H using chimeric methylphosphonodiester/phosphodiester structures. Nucleic Acids Res. 1992 Feb 25;20(4):763–770. doi: 10.1093/nar/20.4.763. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Goodchild J., Carroll E., 3rd, Greenberg J. R. Inhibition of rabbit beta-globin synthesis by complementary oligonucleotides: identification of mRNA sites sensitive to inhibition. Arch Biochem Biophys. 1988 Jun;263(2):401–409. doi: 10.1016/0003-9861(88)90652-2. [DOI] [PubMed] [Google Scholar]
  21. Griffin L. C., Dervan P. B. Recognition of thymine adenine.base pairs by guanine in a pyrimidine triple helix motif. Science. 1989 Sep 1;245(4921):967–971. doi: 10.1126/science.2549639. [DOI] [PubMed] [Google Scholar]
  22. Grunicke H. H. The cell membrane as a target for cancer chemotherapy. Eur J Cancer. 1991;27(3):281–284. doi: 10.1016/0277-5379(91)90516-g. [DOI] [PubMed] [Google Scholar]
  23. Gutierrez A. A., Lemoine N. R., Sikora K. Gene therapy for cancer. Lancet. 1992 Mar 21;339(8795):715–721. doi: 10.1016/0140-6736(92)90606-4. [DOI] [PubMed] [Google Scholar]
  24. Hanvey J. C., Peffer N. J., Bisi J. E., Thomson S. A., Cadilla R., Josey J. A., Ricca D. J., Hassman C. F., Bonham M. A., Au K. G. Antisense and antigene properties of peptide nucleic acids. Science. 1992 Nov 27;258(5087):1481–1485. doi: 10.1126/science.1279811. [DOI] [PubMed] [Google Scholar]
  25. Harel-Bellan A., Brini A. T., Ferris D. K., Robin P., Farrar W. L. In situ detection of a heat-shock regulatory element binding protein using a soluble synthetic enhancer sequence. Nucleic Acids Res. 1989 Jun 12;17(11):4077–4087. doi: 10.1093/nar/17.11.4077. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Harel-Bellan A., Durum S., Muegge K., Abbas A. K., Farrar W. L. Specific inhibition of lymphokine biosynthesis and autocrine growth using antisense oligonucleotides in Th1 and Th2 helper T cell clones. J Exp Med. 1988 Dec 1;168(6):2309–2318. doi: 10.1084/jem.168.6.2309. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Herschlag D. Implications of ribozyme kinetics for targeting the cleavage of specific RNA molecules in vivo: more isn't always better. Proc Natl Acad Sci U S A. 1991 Aug 15;88(16):6921–6925. doi: 10.1073/pnas.88.16.6921. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Holt J. T., Redner R. L., Nienhuis A. W. An oligomer complementary to c-myc mRNA inhibits proliferation of HL-60 promyelocytic cells and induces differentiation. Mol Cell Biol. 1988 Feb;8(2):963–973. doi: 10.1128/mcb.8.2.963. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Hélène C., Toulmé J. J. Specific regulation of gene expression by antisense, sense and antigene nucleic acids. Biochim Biophys Acta. 1990 Jun 21;1049(2):99–125. doi: 10.1016/0167-4781(90)90031-v. [DOI] [PubMed] [Google Scholar]
  30. Jaskulski D., deRiel J. K., Mercer W. E., Calabretta B., Baserga R. Inhibition of cellular proliferation by antisense oligodeoxynucleotides to PCNA cyclin. Science. 1988 Jun 10;240(4858):1544–1546. doi: 10.1126/science.2897717. [DOI] [PubMed] [Google Scholar]
  31. Kasid U., Pfeifer A., Brennan T., Beckett M., Weichselbaum R. R., Dritschilo A., Mark G. E. Effect of antisense c-raf-1 on tumorigenicity and radiation sensitivity of a human squamous carcinoma. Science. 1989 Mar 10;243(4896):1354–1356. doi: 10.1126/science.2466340. [DOI] [PubMed] [Google Scholar]
  32. Koizumi M., Kamiya H., Ohtsuka E. Ribozymes designed to inhibit transformation of NIH3T3 cells by the activated c-Ha-ras gene. Gene. 1992 Aug 15;117(2):179–184. doi: 10.1016/0378-1119(92)90727-7. [DOI] [PubMed] [Google Scholar]
  33. Loke S. L., Stein C. A., Zhang X. H., Mori K., Nakanishi M., Subasinghe C., Cohen J. S., Neckers L. M. Characterization of oligonucleotide transport into living cells. Proc Natl Acad Sci U S A. 1989 May;86(10):3474–3478. doi: 10.1073/pnas.86.10.3474. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Loke S. L., Stein C., Zhang X., Avigan M., Cohen J., Neckers L. M. Delivery of c-myc antisense phosphorothioate oligodeoxynucleotides to hematopoietic cells in culture by liposome fusion: specific reduction in c-myc protein expression correlates with inhibition of cell growth and DNA synthesis. Curr Top Microbiol Immunol. 1988;141:282–289. doi: 10.1007/978-3-642-74006-0_38. [DOI] [PubMed] [Google Scholar]
  35. Mergny J. L., Duval-Valentin G., Nguyen C. H., Perrouault L., Faucon B., Rougée M., Montenay-Garestier T., Bisagni E., Hélène C. Triple helix-specific ligands. Science. 1992 Jun 19;256(5064):1681–1684. doi: 10.1126/science.256.5064.1681. [DOI] [PubMed] [Google Scholar]
  36. Miller A. D. Human gene therapy comes of age. Nature. 1992 Jun 11;357(6378):455–460. doi: 10.1038/357455a0. [DOI] [PubMed] [Google Scholar]
  37. Moroni M. C., Willingham M. C., Beguinot L. EGF-R antisense RNA blocks expression of the epidermal growth factor receptor and suppresses the transforming phenotype of a human carcinoma cell line. J Biol Chem. 1992 Feb 5;267(4):2714–2722. [PubMed] [Google Scholar]
  38. Mukhopadhyay T., Tainsky M., Cavender A. C., Roth J. A. Specific inhibition of K-ras expression and tumorigenicity of lung cancer cells by antisense RNA. Cancer Res. 1991 Mar 15;51(6):1744–1748. [PubMed] [Google Scholar]
  39. Murphy P. R., Sato Y., Knee R. S. Phosphorothioate antisense oligonucleotides against basic fibroblast growth factor inhibit anchorage-dependent and anchorage-independent growth of a malignant glioblastoma cell line. Mol Endocrinol. 1992 Jun;6(6):877–884. doi: 10.1210/mend.6.6.1323055. [DOI] [PubMed] [Google Scholar]
  40. Nguyen C. H., Lavelle F., Riou J. F., Bissery M. C., Huel C., Bisagni E. Further SAR in the new antitumor 1-amino-substituted gamma-carbolines and 5H-benzo[e]pyrido[4,3-b]indoles series. Anticancer Drug Des. 1992 Jun;7(3):235–251. [PubMed] [Google Scholar]
  41. Nielsen P. E., Egholm M., Berg R. H., Buchardt O. Sequence-selective recognition of DNA by strand displacement with a thymine-substituted polyamide. Science. 1991 Dec 6;254(5037):1497–1500. doi: 10.1126/science.1962210. [DOI] [PubMed] [Google Scholar]
  42. Perlaky L., Valdez B. C., Busch R. K., Larson R. G., Jhiang S. M., Zhang W. W., Brattain M., Busch H. Increased growth of NIH/3T3 cells by transfection with human p120 complementary DNA and inhibition by a p120 antisense construct. Cancer Res. 1992 Jan 15;52(2):428–436. [PubMed] [Google Scholar]
  43. Rothenberg M., Johnson G., Laughlin C., Green I., Cradock J., Sarver N., Cohen J. S. Oligodeoxynucleotides as anti-sense inhibitors of gene expression: therapeutic implications. J Natl Cancer Inst. 1989 Oct 18;81(20):1539–1544. doi: 10.1093/jnci/81.20.1539. [DOI] [PubMed] [Google Scholar]
  44. Saison-Behmoaras T., Tocqué B., Rey I., Chassignol M., Thuong N. T., Hélène C. Short modified antisense oligonucleotides directed against Ha-ras point mutation induce selective cleavage of the mRNA and inhibit T24 cells proliferation. EMBO J. 1991 May;10(5):1111–1118. doi: 10.1002/j.1460-2075.1991.tb08051.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  45. Scanlon K. J., Jiao L., Funato T., Wang W., Tone T., Rossi J. J., Kashani-Sabet M. Ribozyme-mediated cleavage of c-fos mRNA reduces gene expression of DNA synthesis enzymes and metallothionein. Proc Natl Acad Sci U S A. 1991 Dec 1;88(23):10591–10595. doi: 10.1073/pnas.88.23.10591. [DOI] [PMC free article] [PubMed] [Google Scholar]
  46. Schwab G., Siegall C. B., Aarden L. A., Neckers L. M., Nordan R. P. Characterization of an interleukin-6-mediated autocrine growth loop in the human multiple myeloma cell line, U266. Blood. 1991 Feb 1;77(3):587–593. [PubMed] [Google Scholar]
  47. Skorski T., Szczylik C., Ratajczak M. Z., Malaguarnera L., Gewirtz A. M., Calabretta B. Growth factor-dependent inhibition of normal hematopoiesis by N-ras antisense oligodeoxynucleotides. J Exp Med. 1992 Mar 1;175(3):743–750. doi: 10.1084/jem.175.3.743. [DOI] [PMC free article] [PubMed] [Google Scholar]
  48. Stein C. A., Cohen J. S. Oligodeoxynucleotides as inhibitors of gene expression: a review. Cancer Res. 1988 May 15;48(10):2659–2668. [PubMed] [Google Scholar]
  49. Stein C. A., Mori K., Loke S. L., Subasinghe C., Shinozuka K., Cohen J. S., Neckers L. M. Phosphorothioate and normal oligodeoxyribonucleotides with 5'-linked acridine: characterization and preliminary kinetics of cellular uptake. Gene. 1988 Dec 10;72(1-2):333–341. doi: 10.1016/0378-1119(88)90160-6. [DOI] [PubMed] [Google Scholar]
  50. Szczylik C., Skorski T., Nicolaides N. C., Manzella L., Malaguarnera L., Venturelli D., Gewirtz A. M., Calabretta B. Selective inhibition of leukemia cell proliferation by BCR-ABL antisense oligodeoxynucleotides. Science. 1991 Aug 2;253(5019):562–565. doi: 10.1126/science.1857987. [DOI] [PubMed] [Google Scholar]
  51. Tidd D. M. A potential role for antisense oligonucleotide analogues in the development of oncogene targeted cancer chemotherapy. Anticancer Res. 1990 Sep-Oct;10(5A):1169–1182. [PubMed] [Google Scholar]
  52. Tidd D. M., Hawley P., Warenius H. M., Gibson I. Evaluation of N-ras oncogene anti-sense, sense and nonsense sequence methylphosphonate oligonucleotide analogues. Anticancer Drug Des. 1988 Aug;3(2):117–127. [PubMed] [Google Scholar]
  53. Wickstrom E. L., Bacon T. A., Gonzalez A., Freeman D. L., Lyman G. H., Wickstrom E. Human promyelocytic leukemia HL-60 cell proliferation and c-myc protein expression are inhibited by an antisense pentadecadeoxynucleotide targeted against c-myc mRNA. Proc Natl Acad Sci U S A. 1988 Feb;85(4):1028–1032. doi: 10.1073/pnas.85.4.1028. [DOI] [PMC free article] [PubMed] [Google Scholar]
  54. Woolf T. M., Melton D. A., Jennings C. G. Specificity of antisense oligonucleotides in vivo. Proc Natl Acad Sci U S A. 1992 Aug 15;89(16):7305–7309. doi: 10.1073/pnas.89.16.7305. [DOI] [PMC free article] [PubMed] [Google Scholar]
  55. Wu J., Zhu J. Q., Han K. K., Zhu D. X. The role of the c-fms oncogene in the regulation of HL-60 cell differentiation. Oncogene. 1990 Jun;5(6):873–877. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES